IL1B and gout: With respect to investigational agents, randomized clinical trials of the IL-1β-specific monoclonal antibody canakinumab have demonstrated superiority compared to a single dose of 40 mg triamcinolone acetonide in reducing pain in acute gout and delaying time to next acute gout flare [71].